Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Free Cash Flow (2023 - 2025)

Mangoceuticals' Free Cash Flow history spans 3 years, with the latest figure at -$1.1 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 4.59% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.9 million, a 20.28% decrease, with the full-year FY2025 number at -$5.9 million, down 20.28% from a year prior.
  • Free Cash Flow hit -$1.1 million in Q4 2025 for Mangoceuticals, up from -$1.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for MGRX hit a ceiling of -$991131.0 in Q1 2024 and a floor of -$2.3 million in Q1 2025.
  • Historically, Free Cash Flow has averaged -$1.5 million across 3 years, with a median of -$1.4 million in 2024.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 45.3% in 2024 and later crashed 129.51% in 2025.
  • Tracing MGRX's Free Cash Flow over 3 years: stood at -$1.7 million in 2023, then soared by 33.47% to -$1.1 million in 2024, then rose by 4.59% to -$1.1 million in 2025.
  • Business Quant data shows Free Cash Flow for MGRX at -$1.1 million in Q4 2025, -$1.2 million in Q3 2025, and -$1.3 million in Q2 2025.